Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Inaugural Process Innovation Asia Pacific to Drive Industry Transformation for South-East Asia's Chemicals and Pharmaceuticals

SINGAPORE, Aug. 22, 2024 /PRNewswire/ -- Organised by Constellar, in partnership with DECHEMA Ausstellungs-GmbH (DECHEMA Exhibitions)[1], the inauguralProcess Innovation Asia Pacific - Powered by ACHEMA (PIA) will be held from19 to 21 November 2024 at Singapore EXPO. The most comprehensive Pr...

2024-08-22 15:30 9294

China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-08-22 08:00 3031

Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption

New Veeva Pulse findings show congresses and early-career experts have the strongest influence on patient outcomes SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outreach maximizes medical affairs te...

2024-08-21 09:00 2714

Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Aug. 20, 2024 /PRNewswire/ -- On August 20, the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) based on the positive results from the pivotal OptiTROP-Lung03 study has been accepted by the Center for Drug Evaluation (CDE)...

2024-08-20 16:32 1573

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

Infinitus Highlights Modernizing Traditional Prescriptions at ICMCM

GUANGZHOU, China, Aug. 20, 2024 /PRNewswire/ -- Recently, the highly-anticipated 23rd International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) took place inHong Kong, bringing together global experts, top researchers and industry leaders in traditional medicine...

2024-08-20 15:09 1558

Infinitus Highlights Modernizing Traditional Prescriptions at ICMCM

Alphamab Oncology Reports 2024 Interim Results and Business Highlights

SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months endedJune 30, 2024 and highlighted recent business progress. Financial Summary * For the six months ended June 30, 2024, we recorded total revenue of RMB ...

2024-08-16 11:18 3336

NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT

HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biop...

2024-08-15 13:43 1793

Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months

* Docquity's Awareness to Advocacy (A2A) Program and strong local distribution network enabled SIT's duo probiotic sales to surpass the market growth rate of 15% * The technology platform boosted SIT's HCP education efforts, more than doubling its reach to 2,000 HCPs within six months and aim...

2024-08-13 10:00 2009

Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE

ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for malignancies, announced today it has been cleared by the Ce...

2024-08-13 09:52 2134

Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial

SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial.This marks the first cell therapy to enter Phase lI trials in both...

2024-08-13 09:00 1782

AI in the IVF Process is the Standard of Care at Virtus Fertility Centre Singapore

The technology developed by Virtus Health's scientists contributes to IVF medicine by shortening the time to a successful pregnancy and improving overall success rates. SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Virtus Fertility Centre Singapore (VFCS) announced that artificial intelligence (AI), ...

2024-08-13 08:44 1788

Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis

HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positive results from its Phase1b clinical study of LNK01004, a skin restricte...

2024-08-13 08:00 1836

Environmental Compliance and Pharmaceutical Quality Standards Pave the Way for Transformational Growth in Chromatography

SAN ANTONIO, Aug. 13, 2024 /PRNewswire/ -- Chromatography instruments and modular test equipment are revolutionising scientific analysis and industrial testing. By enabling precise separation and analysis of complex mixtures, chromatography plays a crucial role in ensuring pharmaceutical purity, ...

2024-08-13 01:30 1685

OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with OcuMension, the "Parties") where OcuMension will acquire or secure commercialization rights inChina to a portfolio of Alcon dr...

2024-08-12 22:01 2509

Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics ( Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the reporting period, the company achieved operating revenue ofRMB 168 million, ...

2024-08-12 21:52 3029

Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024

SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 in patients with platinum-resistant ovarian cancer and patients with advanced HER2-positive (...

2024-08-12 10:18 1836

Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months

2024-08-07 10:05 2278

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

* Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] * Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mo...

2024-08-07 09:00 2206

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...

2024-08-06 18:47 2111

First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis

YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept h...

2024-08-06 17:00 2036

1 ... 7 8 91011 12 13 ... 187